Riccardo Ray Colciago, Research Fellow at the University of Milan-Bicocca, shared a post on LinkedIn:
“Breast Cancer – Key Science Highlights from ASTRO25
- Nodal ultrahypofractionation shows comparable acute toxicities to standard hypofractionation – a potential game changer for selected patients.
- Partial breast irradiation in just 3 fractions may represent the next frontier for PBI, combining efficacy and patient convenience.
- Preoperative stereotactic PBI can safely escalate doses up to 38 Gy, achieving remarkable rates of pathological complete response.
- Omitting radiotherapy could have a significant negative impact even in patients with a low-risk score – underlining the crucial role of RT in treatment.
Exciting times for breast cancer research and clinical practice!”
More posts featuring ASTRO 2025 on OncoDaily.
